DK3098309T3 - Rationelt designet enkeltkædet meganuclease med ikke-palindrome genkendelsessekvenser - Google Patents
Rationelt designet enkeltkædet meganuclease med ikke-palindrome genkendelsessekvenser Download PDFInfo
- Publication number
- DK3098309T3 DK3098309T3 DK16163925.7T DK16163925T DK3098309T3 DK 3098309 T3 DK3098309 T3 DK 3098309T3 DK 16163925 T DK16163925 T DK 16163925T DK 3098309 T3 DK3098309 T3 DK 3098309T3
- Authority
- DK
- Denmark
- Prior art keywords
- single chain
- recognition sequences
- rationally designed
- chain meganuclease
- designed single
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
- C12N9/22—Ribonucleases [RNase]; Deoxyribonucleases [DNase]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/90—Stable introduction of foreign DNA into chromosome
- C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/90—Stable introduction of foreign DNA into chromosome
- C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
- C12N15/907—Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/80—Vectors containing sites for inducing double-stranded breaks, e.g. meganuclease restriction sites
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y301/00—Hydrolases acting on ester bonds (3.1)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y301/00—Hydrolases acting on ester bonds (3.1)
- C12Y301/04—Phosphoric diester hydrolases (3.1.4)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Mycology (AREA)
- Cell Biology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Virology (AREA)
- Enzymes And Modification Thereof (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Breeding Of Plants And Reproduction By Means Of Culturing (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US124707P | 2007-10-31 | 2007-10-31 | |
| EP13165733.0A EP2660317B1 (en) | 2007-10-31 | 2008-10-31 | Rationally-designed single-chain meganucleases with non-palindromic recognition sequences |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK3098309T3 true DK3098309T3 (da) | 2019-07-15 |
Family
ID=40591777
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK16163925.7T DK3098309T3 (da) | 2007-10-31 | 2008-10-31 | Rationelt designet enkeltkædet meganuclease med ikke-palindrome genkendelsessekvenser |
| DK08845549.8T DK2215223T3 (da) | 2007-10-31 | 2008-10-31 | Rationelt konstruerede enkeltkæde-meganucleaser med ikke-palindrome genkendelsessekvenser |
| DK13165733.0T DK2660317T3 (en) | 2007-10-31 | 2008-10-31 | Rationally designed single-chain meganucleases with non-palindromic recognition sequences |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK08845549.8T DK2215223T3 (da) | 2007-10-31 | 2008-10-31 | Rationelt konstruerede enkeltkæde-meganucleaser med ikke-palindrome genkendelsessekvenser |
| DK13165733.0T DK2660317T3 (en) | 2007-10-31 | 2008-10-31 | Rationally designed single-chain meganucleases with non-palindromic recognition sequences |
Country Status (8)
| Country | Link |
|---|---|
| US (10) | US8445251B2 (enExample) |
| EP (4) | EP3098309B1 (enExample) |
| JP (7) | JP5761996B2 (enExample) |
| AU (1) | AU2008318430A1 (enExample) |
| CA (1) | CA2704383A1 (enExample) |
| DK (3) | DK3098309T3 (enExample) |
| ES (3) | ES2732735T3 (enExample) |
| WO (1) | WO2009059195A2 (enExample) |
Families Citing this family (133)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2479153C (en) † | 2002-03-15 | 2015-06-02 | Cellectis | Hybrid and single chain meganucleases and use thereof |
| WO2009095742A1 (en) | 2008-01-31 | 2009-08-06 | Cellectis | New i-crei derived single-chain meganuclease and uses thereof |
| EP3098309B1 (en) | 2007-10-31 | 2019-04-10 | Precision Biosciences, Inc. | Rationally-designed single-chain meganucleases with non-palindromic recognition sequences |
| CN102762726A (zh) | 2009-11-27 | 2012-10-31 | 巴斯夫植物科学有限公司 | 嵌合内切核酸酶及其用途 |
| CN102725412B (zh) | 2009-11-27 | 2017-09-22 | 巴斯夫植物科学有限公司 | 优化的内切核酸酶及其用途 |
| AU2010325563B2 (en) | 2009-11-27 | 2017-02-02 | Basf Plant Science Company Gmbh | Chimeric endonucleases and uses thereof |
| JP2013526844A (ja) | 2010-03-22 | 2013-06-27 | フィリップ・モーリス・プロダクツ・ソシエテ・アノニム | 植物の酵素活性の改変 |
| WO2012138901A1 (en) * | 2011-04-05 | 2012-10-11 | Cellectis Sa | Method for enhancing rare-cutting endonuclease efficiency and uses thereof |
| WO2012167192A2 (en) | 2011-06-01 | 2012-12-06 | Precision Biosciences, Inc. | Methods and products for producing engineered mammalian cell lines with amplified transgenes |
| EP2612918A1 (en) | 2012-01-06 | 2013-07-10 | BASF Plant Science Company GmbH | In planta recombination |
| CA2872096A1 (en) | 2012-05-04 | 2013-11-07 | E. I. Du Pont De Nemours And Company | Compositions and methods comprising sequences having meganuclease activity |
| EP3858376B1 (en) | 2014-03-12 | 2025-07-30 | Precision Biosciences, Inc. | Dystrophin gene exon deletion using engineered nucleases |
| KR20240123409A (ko) | 2014-09-07 | 2024-08-13 | 셀렉타 바이오사이언시즈, 인크. | 유전자 편집 항-바이러스 전달 벡터 면역 반응을 약화시키기 위한 방법 및 조성물 |
| ES2905181T3 (es) | 2015-05-01 | 2022-04-07 | Prec Biosciences Inc | Deleción precisa de secuencias cromosómicas in vivo |
| FI3447075T3 (fi) | 2015-05-15 | 2023-11-07 | Massachusetts Gen Hospital | Antagonistisia anti-tuumorinekroositekijäreseptorin superperheen vasta-aineita |
| DK3310369T3 (da) | 2015-06-19 | 2022-06-20 | Prec Biosciences Inc | Selvbegrænsende virale vektorer, der koder for nukleaser |
| WO2016210292A1 (en) | 2015-06-25 | 2016-12-29 | Children's Medical Center Corporation | Methods and compositions relating to hematopoietic stem cell expansion, enrichment, and maintenance |
| EP3334750B1 (en) | 2015-08-11 | 2022-10-05 | Anie Philip | Peptidic tgf-beta antagonists |
| JP6775584B2 (ja) | 2015-09-08 | 2020-10-28 | プレシジョン バイオサイエンシズ，インク． | 設計されたメガヌクレアーゼを使用した網膜色素変性症の治療 |
| IL287319B2 (en) | 2015-10-05 | 2023-02-01 | Prec Biosciences Inc | Genetically-modified cells comprising a modified human t cell receptor alpha constant region gene |
| ES2883116T3 (es) | 2015-10-05 | 2021-12-07 | Prec Biosciences Inc | Meganucleasas diseñadas con secuencias de reconocimiento encontradas en el gen de la región constante alfa del receptor de células T humanas |
| CA3009637A1 (en) | 2015-12-23 | 2017-06-29 | Precision Biosciences, Inc. | Engineered meganucleases with recognition sequences found in the human beta-2 microglobulin gene |
| US11274288B2 (en) | 2016-02-16 | 2022-03-15 | Emendobio Inc. | Compositions and methods for promoting homology directed repair mediated gene editing |
| US20190119642A1 (en) | 2016-03-15 | 2019-04-25 | Children's Medical Center Corporation | Methods and compositions relating to hematopoietic stem cell expansion |
| DE212017000118U1 (de) | 2016-04-27 | 2018-12-05 | University Of Puerto Rico | 1,5-Disubstituierte 1,2,3-Triazole sind Inhibitoren von Rac/Cdc42-GTPasen |
| AU2017260426B2 (en) | 2016-05-03 | 2023-08-31 | Precision Biosciences, Inc. | Engineered nucleases useful for treatment of hemophilia A |
| MX2018015798A (es) | 2016-06-22 | 2019-07-12 | Univ North Carolina State | Método para incrementar la eficiencia de uso de nitrógeno y/o la eficiencia de utilización de nitrógeno en plantas. |
| JP2019525759A (ja) * | 2016-07-25 | 2019-09-12 | ブルーバード バイオ， インコーポレイテッド | Ｂｃｌ１１ａホーミングエンドヌクレアーゼバリアント、組成物、および使用方法 |
| WO2018039333A1 (en) | 2016-08-23 | 2018-03-01 | Bluebird Bio, Inc. | Tim3 homing endonuclease variants, compositions, and methods of use |
| SG11201901757YA (en) | 2016-09-08 | 2019-03-28 | Bluebird Bio Inc | Pd-1 homing endonuclease variants, compositions, and methods of use |
| DK3523326T3 (da) | 2016-10-04 | 2020-08-03 | Prec Biosciences Inc | Samstimulerende domæner til anvendelse i genetisk modificerede celler |
| FI3526323T3 (fi) | 2016-10-14 | 2023-06-06 | Prec Biosciences Inc | Hepatiitti B -viruksen genomissa oleville tunnistussekvensseille spesifisiä muokattuja meganukleaaseja |
| WO2018075541A1 (en) * | 2016-10-17 | 2018-04-26 | Bluebird Bio, Inc. | TGFβR2 ENDONUCLEASE VARIANTS, COMPOSITIONS, AND METHODS OF USE |
| WO2018073393A2 (en) | 2016-10-19 | 2018-04-26 | Cellectis | Tal-effector nuclease (talen) -modified allogenic cells suitable for therapy |
| BR112019021282A2 (pt) | 2017-04-12 | 2020-05-19 | Magenta Therapeutics Inc | antagonistas de receptor aril hidrocarboneto e usos dos mesmos |
| WO2018195449A1 (en) * | 2017-04-21 | 2018-10-25 | Precision Biosciences, Inc. | Engineered meganucleases specific for recognition sequences in the pcsk9 gene |
| WO2018201144A1 (en) | 2017-04-28 | 2018-11-01 | Precision Biosciences, Inc. | Methods for reducing dna-induced cytotoxicity and enhancing gene editing in primary cells |
| JP7170666B2 (ja) | 2017-05-08 | 2022-11-14 | プレシジョン バイオサイエンシズ，インク． | 操作された抗原受容体をコードする核酸分子及び阻害性核酸分子、並びにそれらの使用方法 |
| MA48797A (fr) | 2017-05-25 | 2020-04-08 | Bluebird Bio Inc | Variants de l'endonucléase cblb , compositions et procédés d'utilisation |
| IL271516B2 (en) | 2017-06-23 | 2024-10-01 | Univ Kentucky Res Found | A method for modulating the alkaloid content of a plant, a method for producing a plant and a modified plant |
| JP2020529834A (ja) | 2017-06-30 | 2020-10-15 | プレシジョン バイオサイエンシズ，インク． | Ｔ細胞受容体アルファ遺伝子の改変されたイントロンを含む遺伝子改変ｔ細胞 |
| US20190093117A1 (en) | 2017-07-31 | 2019-03-28 | R. J. Reynolds Tobacco Company | Methods and compositions for viral-based gene editing in plants |
| US20200239544A1 (en) | 2017-10-03 | 2020-07-30 | Precision Biosciences, Inc. | Modified epidermal growth factor receptor peptides for use in genetically-modified cells |
| US11779654B2 (en) | 2017-10-04 | 2023-10-10 | 2Seventy Bio, Inc. | PCSK9 endonuclease variants, compositions, and methods of use |
| MX2020003838A (es) | 2017-10-13 | 2020-08-06 | Selecta Biosciences Inc | Metodos y composiciones para atenuar las respuestas de inmunoglobulina m del vector de transferencia antiviral. |
| US20190343885A1 (en) | 2017-10-31 | 2019-11-14 | Magenta Therapeutics Inc. | Compositions and methods for hematopoietic stem and progenitor cell transplant therapy |
| WO2019089826A1 (en) | 2017-10-31 | 2019-05-09 | Magenta Therapeutics Inc. | Compositions and methods for the expansion of hematopoietic stem and progenitor cells |
| WO2019089913A1 (en) | 2017-11-01 | 2019-05-09 | Precision Biosciences, Inc. | Engineered nucleases that target human and canine factor viii genes as a treatment for hemophilia a |
| IL315735A (en) | 2017-12-06 | 2024-11-01 | Ensoma Inc | Dosing Regimens for the Mobilization of Hematopoietic Stem and Progenitor Cells |
| WO2019126555A1 (en) * | 2017-12-20 | 2019-06-27 | Bluebird Bio, Inc. | Ctla4 homing endonuclease variants, compositions, and methods of use |
| EP3735412B1 (en) | 2018-01-03 | 2024-02-21 | EdiGene Biotechnology, Inc. | Compositions and methods for the expansion of hematopoietic stem and progenitor cells and treatment of inherited metabolic disorders |
| CN111819285B (zh) | 2018-01-09 | 2024-08-09 | 希博斯美国有限公司 | 防碎基因和突变 |
| KR20200139679A (ko) | 2018-02-26 | 2020-12-14 | 안톨알엑스, 인크. | 면역관용성 리포솜 및 그의 사용 방법 |
| WO2019195611A1 (en) | 2018-04-04 | 2019-10-10 | Cibus Us Llc | Fad2 genes and mutations |
| IT201800004253A1 (it) | 2018-04-05 | 2019-10-05 | Composizioni e metodi per il trattamento della tachicardia ventricolare polimorfa catecolaminergica dominante ereditaria. | |
| US11142750B2 (en) | 2018-04-12 | 2021-10-12 | Precision Biosciences, Inc. | Optimized engineered meganucleases having specificity for a recognition sequence in the Hepatitis B virus genome |
| MX2020010795A (es) | 2018-04-12 | 2021-01-08 | Prec Biosciences Inc | Nucleasas modificadas genéticamente optimizadas que tienen especificidad para el gen de la región constante alfa del receptor de linfocitos t humanos. |
| EP3784790A4 (en) * | 2018-04-27 | 2022-02-09 | Seattle Children's Hospital d/b/a Seattle Children's Research Institute | BRUTON TYROSINE KINASE HOMING ENDONUCLEAR VARIANTS, COMPOSITIONS AND METHOD OF USE |
| AU2019287720B2 (en) | 2018-06-14 | 2025-08-28 | Regeneron Pharmaceuticals, Inc. | CD79A chimeric antigen receptors |
| GB201812603D0 (en) | 2018-08-02 | 2018-09-19 | British American Tobacco Investments Ltd | Method |
| SG11202102208WA (en) | 2018-09-04 | 2021-04-29 | Magenta Therapeutics Inc | Aryl hydrocarbon receptor antagonists and methods of use |
| WO2020072059A1 (en) | 2018-10-04 | 2020-04-09 | Bluebird Bio, Inc. | Cblb endonuclease variants, compositions, and methods of use |
| GB201817971D0 (en) | 2018-11-02 | 2018-12-19 | British American Tobacco Investments Ltd | Method |
| GB201818715D0 (en) | 2018-11-16 | 2019-01-02 | British American Tobacco Investments Ltd | Method |
| KR20210102925A (ko) | 2018-12-10 | 2021-08-20 | 블루버드 바이오, 인코포레이티드. | 호밍 엔도뉴클레아제 변이체 |
| US20220090047A1 (en) | 2018-12-21 | 2022-03-24 | Precision Biosciences, Inc. | Genetic modification of the hydroxyacid oxidase 1 gene for treatment of primary hyperoxaluria |
| GB201900940D0 (en) | 2019-01-23 | 2019-03-13 | British American Tobacco Investments Ltd | Method |
| IL316764A (en) | 2019-04-03 | 2025-01-01 | Prec Biosciences Inc | Genetically modified immune cells containing shRNA-targeted microRNA (shRNAmir) |
| US20220204994A1 (en) | 2019-04-05 | 2022-06-30 | Precision Biosciences, Inc. | Methods of preparing populations of genetically-modified immune cells |
| CN114026228A (zh) | 2019-05-07 | 2022-02-08 | 精密生物科学公司 | 用于识别序列的工程化大范围核酸酶的优化 |
| GB201906768D0 (en) | 2019-05-14 | 2019-06-26 | British American Tobacco Investments Ltd | Method |
| KR20220015425A (ko) | 2019-05-28 | 2022-02-08 | 셀렉타 바이오사이언시즈, 인크. | 약화된 항바이러스 전달 벡터 면역 반응을 위한 방법 및 조성물 |
| GB201909562D0 (en) | 2019-07-03 | 2019-08-14 | British American Tobacco Investments Ltd | Method |
| GB201909563D0 (en) | 2019-07-03 | 2019-08-14 | British American Tobacco Investments Ltd | Method |
| WO2021035054A1 (en) | 2019-08-20 | 2021-02-25 | Precision Biosciences, Inc. | Lymphodepletion dosing regimens for cellular immunotherapies |
| WO2021087305A1 (en) | 2019-10-30 | 2021-05-06 | Precision Biosciences, Inc. | Cd20 chimeric antigen receptors and methods of use for immunotherapy |
| WO2021087406A1 (en) | 2019-11-01 | 2021-05-06 | Magenta Therapeutics, Inc. | Dosing regimens for the mobilization of hematopoietic stem and progentor cells |
| WO2021113765A1 (en) | 2019-12-06 | 2021-06-10 | Precision Biosciences, Inc. | Optimized engineered meganucleases having specificity for a recognition sequence in the hepatitis b virus genome |
| EP3835309A1 (en) | 2019-12-13 | 2021-06-16 | KWS SAAT SE & Co. KGaA | Method for increasing cold or frost tolerance in a plant |
| WO2021158915A1 (en) | 2020-02-06 | 2021-08-12 | Precision Biosciences, Inc. | Recombinant adeno-associated virus compositions and methods for producing and using the same |
| JP2023521055A (ja) | 2020-04-09 | 2023-05-23 | アール・ジエイ・レイノルズ・タバコ・カンパニー | ニコチアナ・タバカムにおけるニコチンレベルの調整方法 |
| MX2022013493A (es) | 2020-04-27 | 2023-02-22 | Magenta Therapeutics Inc | Metodos y composiciones para transducir celulas madre y progenitoras hematopoyeticas in vivo. |
| US20230183664A1 (en) | 2020-05-11 | 2023-06-15 | Precision Biosciences, Inc. | Self-limiting viral vectors encoding nucleases |
| CN115803064A (zh) | 2020-05-12 | 2023-03-14 | 宾夕法尼亚州大学信托人 | 用于drg特异性降低转基因表达的组合物 |
| WO2021231495A1 (en) | 2020-05-12 | 2021-11-18 | Precision Biosciences, Inc. | Treatment of retinitis pigmentosa using improved engineered meganucleases |
| EP4192875A1 (en) | 2020-08-10 | 2023-06-14 | Precision BioSciences, Inc. | Antibodies and fragments specific for b-cell maturation antigen and uses thereof |
| US20240011003A1 (en) | 2020-08-21 | 2024-01-11 | Precision Biosciences, Inc. | Engineered meganucleases having specificity for a recognition sequence in the transthyretin gene |
| US20230365995A1 (en) | 2020-10-07 | 2023-11-16 | Precision Biosciences, Inc. | Lipid nanoparticle compositions |
| TW202233844A (zh) | 2020-10-29 | 2022-09-01 | 賓州大學委員會 | Aav衣殼及含有其之組成物 |
| MX2023005496A (es) | 2020-11-12 | 2023-08-04 | Prec Biosciences Inc | Meganucleasas manipuladas genéticamente que tienen especifidad para secuencias de reconocimiento en el gen de la distrofina. |
| CA3172161A1 (en) | 2021-01-08 | 2022-07-14 | James Jefferson Smith | Engineered meganucleases having specificity for a recognition sequence in the hydroxyacid oxidase 1 gene |
| US20250127811A1 (en) | 2021-01-28 | 2025-04-24 | Precision Biosciences, Inc. | Modulation of tgf beta signaling in genetically-modified eukaryotic cells |
| WO2022197776A1 (en) | 2021-03-16 | 2022-09-22 | Magenta Therapeutics, Inc. | Dosing regimens for hematopoietic stem cell mobilization for stem cell transplants in multiple myeloma patients |
| CA3173051A1 (en) | 2021-04-22 | 2022-10-22 | Precision Biosciences, Inc. | Engineered meganucleases that target human mitochondrial genomes |
| IL307834A (en) | 2021-04-22 | 2023-12-01 | Prec Biosciences Inc | Transgenic meganonucleases targeting human mitochondrial genomes |
| WO2022226316A1 (en) | 2021-04-22 | 2022-10-27 | Precision Biosciences, Inc. | Compositions and methods for generating male sterile plants |
| TW202309066A (zh) | 2021-04-27 | 2023-03-01 | 賓州大學委員會 | 衍生自豬的腺相關病毒衣殼及其用途 |
| US20230141563A1 (en) | 2021-10-12 | 2023-05-11 | Selecta Biosciences, Inc. | Methods and compositions for attenuating anti-viral transfer vector igm responses |
| US20240408235A1 (en) | 2021-10-19 | 2024-12-12 | Precision Biosciences, Inc. | Gene editing methods for treating alpha-1 antitrypsin (aat) deficiency |
| WO2023070002A2 (en) | 2021-10-19 | 2023-04-27 | Precision Biosciences, Inc. | Gene editing methods for treating alpha-1 antitrypsin (aat) deficiency |
| WO2023087019A2 (en) | 2021-11-15 | 2023-05-19 | The Trustees Of The University Of Pennsylvania | Compositions for drg-specific reduction of transgene expression |
| EP4472407A1 (en) | 2022-02-03 | 2024-12-11 | Nicoventures Trading Limited | Method of modulating alkaloid content in tobacco plants |
| JP2025505601A (ja) | 2022-02-03 | 2025-02-28 | ニコベンチャーズ トレーディング リミテッド | タバコ植物のアルカロイド含有量を調節する方法 |
| CA3243712A1 (en) | 2022-02-04 | 2023-08-10 | Nicoventures Trading Limited | METHOD FOR MODULATING THE ALKALID CONTENT IN TOBACCO PLANTS |
| US20230357437A1 (en) | 2022-03-09 | 2023-11-09 | Selecta Biosciences, Inc. | Immunosuppressants in combination with anti-igm agents and related dosing |
| GB202205148D0 (en) | 2022-04-07 | 2022-05-25 | Nicoventures Trading Ltd | Method |
| GB202205149D0 (en) | 2022-04-07 | 2022-05-25 | Nicoventures Trading Ltd | Method |
| GB202205562D0 (en) | 2022-04-14 | 2022-06-01 | Nicoventures Trading Ltd | Method |
| GB202205561D0 (en) | 2022-04-14 | 2022-06-01 | Nicoventures Trading Ltd | Method |
| GB202206107D0 (en) | 2022-04-27 | 2022-06-08 | Nicoventures Trading Ltd | Method |
| GB202206109D0 (en) | 2022-04-27 | 2022-06-08 | Nicoventures Trading Ltd | Method |
| WO2023215498A2 (en) | 2022-05-05 | 2023-11-09 | Modernatx, Inc. | Compositions and methods for cd28 antagonism |
| WO2024015966A2 (en) | 2022-07-15 | 2024-01-18 | The Trustees Of The University Of Pennsylvania | Recombinant aav having aav clade d and clade e capsids and compositions containing same |
| EP4587568A2 (en) | 2022-09-16 | 2025-07-23 | King's College London | Compositions and methods for treating neurological diseases |
| WO2024097639A1 (en) | 2022-10-31 | 2024-05-10 | Modernatx, Inc. | Hsa-binding antibodies and binding proteins and uses thereof |
| WO2024118866A1 (en) | 2022-12-01 | 2024-06-06 | Modernatx, Inc. | Gpc3-specific antibodies, binding domains, and related proteins and uses thereof |
| CN120752337A (zh) | 2022-12-14 | 2025-10-03 | 伦敦王室学院 | 用于治疗神经疾病的组合物和方法 |
| WO2024148167A1 (en) | 2023-01-05 | 2024-07-11 | Precision Biosciences, Inc. | Optimized engineered meganucleases having specificity for the human t cell receptor alpha constant region gene |
| GB202300905D0 (en) | 2023-01-20 | 2023-03-08 | Nicoventures Trading Ltd | Method |
| WO2024161022A2 (en) | 2023-02-03 | 2024-08-08 | King's College London | Compositions and methods for treating neurological diseases |
| WO2024167814A1 (en) | 2023-02-06 | 2024-08-15 | Bluerock Therapeutics Lp | Degron fusion proteins and methods of production and use thereof |
| AU2024229544A1 (en) | 2023-03-02 | 2025-10-16 | Alloy Therapeutics, Inc. | Anti-cd22 antibodies and uses thereof |
| GB202303077D0 (en) | 2023-03-02 | 2023-04-19 | Univ Oslo | Brassica plants with improved seed retention |
| WO2024216116A1 (en) | 2023-04-14 | 2024-10-17 | Precision Biosciences, Inc. | Muscle-specific expression cassettes |
| WO2024216118A1 (en) | 2023-04-14 | 2024-10-17 | Precision Biosciences, Inc. | Muscle-specific expression cassettes |
| WO2024236547A1 (en) | 2023-05-18 | 2024-11-21 | Inceptor Bio, Llc | Modified phagocytic cells expressing chimeric antigen receptors comprising a herpes virus entry mediator (hvem) co-stimulatory domain and uses thereof |
| WO2025046513A1 (en) | 2023-08-29 | 2025-03-06 | Inceptor Bio, Llc | Methods of manufacturing myeloid-derived cells from hematopoietic stem cells and compositions and uses thereof |
| WO2025083169A1 (en) | 2023-10-17 | 2025-04-24 | Tenpoint Therapeutics Limited | Combination of a vegf inhibitor and a complement pathway inhibitor for treating ocular disorders |
| WO2025101946A1 (en) * | 2023-11-08 | 2025-05-15 | Precision Biosciences, Inc. | Polypeptide linkers for use in engineered meganucleases |
| WO2025126153A2 (en) | 2023-12-14 | 2025-06-19 | Aviadobio Ltd. | Compositions and methods for treating sod1-mediated neurological diseases |
| WO2025233894A1 (en) | 2024-05-09 | 2025-11-13 | University Of Miami | Engineered meganucleases that target human mitochondrial genomes |
| WO2026006495A1 (en) | 2024-06-25 | 2026-01-02 | Alloy Therapeutics, Inc. | Anti-wt1/hla-a2 antibody and uses thereof |
| WO2026006492A2 (en) | 2024-06-25 | 2026-01-02 | Ypsilon Therapeutics, Inc. | Anti-prame/hla-a2 antibodies and uses thereof |
Family Cites Families (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3751873T2 (de) | 1986-04-09 | 1997-02-13 | Genzyme Corp | Genetisch transformierte Tiere, die ein gewünschtes Protein in Milch absondern |
| US4873316A (en) | 1987-06-23 | 1989-10-10 | Biogen, Inc. | Isolation of exogenous recombinant proteins from the milk of transgenic mammals |
| US6156304A (en) | 1990-12-20 | 2000-12-05 | University Of Pittsburgh Of The Commonwealth System Of Higher Education | Gene transfer for studying and treating a connective tissue of a mammalian host |
| US5384253A (en) | 1990-12-28 | 1995-01-24 | Dekalb Genetics Corporation | Genetic transformation of maize cells by electroporation of cells pretreated with pectin degrading enzymes |
| US5997861A (en) | 1994-10-31 | 1999-12-07 | Burstein Laboratories, Inc. | Antiviral supramolecules containing target-binding molecules and therapeutic molecules bound to spectrin |
| US6056973A (en) | 1996-10-11 | 2000-05-02 | Sequus Pharmaceuticals, Inc. | Therapeutic liposome composition and method of preparation |
| US6060082A (en) | 1997-04-18 | 2000-05-09 | Massachusetts Institute Of Technology | Polymerized liposomes targeted to M cells and useful for oral or mucosal drug delivery |
| US6511676B1 (en) | 1999-11-05 | 2003-01-28 | Teni Boulikas | Therapy for human cancers using cisplatin and other drugs or genes encapsulated into liposomes |
| US6593308B2 (en) | 1999-12-03 | 2003-07-15 | The Regents Of The University Of California | Targeted drug delivery with a hyaluronan ligand |
| WO2002099105A2 (en) * | 2001-06-05 | 2002-12-12 | Cellectis | Methods for modifying the cpg content of polynucleotides |
| JP2005523001A (ja) * | 2002-02-11 | 2005-08-04 | ザイモジェネティクス，インコーポレイティド | 二量体増殖因子を調製するための材料と方法 |
| WO2009095742A1 (en) | 2008-01-31 | 2009-08-06 | Cellectis | New i-crei derived single-chain meganuclease and uses thereof |
| CA2479153C (en) * | 2002-03-15 | 2015-06-02 | Cellectis | Hybrid and single chain meganucleases and use thereof |
| JP4966006B2 (ja) * | 2003-01-28 | 2012-07-04 | セレクティス | カスタムメイドメガヌクレアーゼおよびその使用 |
| JP4095622B2 (ja) * | 2004-03-31 | 2008-06-04 | キヤノン株式会社 | 金結合性複合タンパク質 |
| EP1591521A1 (en) * | 2004-04-30 | 2005-11-02 | Cellectis | I-Dmo I derivatives with enhanced activity at 37 degrees C and use thereof |
| WO2006097853A1 (en) | 2005-03-15 | 2006-09-21 | Cellectis | I-crei meganuclease variants with modified specificity, method of preparation and uses thereof |
| WO2006097784A1 (en) | 2005-03-15 | 2006-09-21 | Cellectis | I-crei meganuclease variants with modified specificity, method of preparation and uses thereof |
| WO2007034262A1 (en) | 2005-09-19 | 2007-03-29 | Cellectis | Heterodimeric meganucleases and use thereof |
| EP1764414A1 (en) * | 2005-09-17 | 2007-03-21 | Icon Genetics AG | Plant viral particles comprising a plurality of fusion proteins consisting of a plant viral coat protein, a peptide linker and a recombinant protein and use of such plant viral particles for protein purification |
| CA3055968A1 (en) | 2005-10-18 | 2007-04-26 | Duke University | Rationally-designed meganucleases with altered sequence specificity and dna-binding affinity |
| WO2007060495A1 (en) | 2005-10-25 | 2007-05-31 | Cellectis | I-crei homing endonuclease variants having novel cleavage specificity and use thereof |
| WO2007049095A1 (en) | 2005-10-25 | 2007-05-03 | Cellectis | Laglidadg homing endonuclease variants having mutations in two functional subdomains and use thereof |
| JP5390189B2 (ja) * | 2005-11-29 | 2014-01-15 | ヴァージニア コモンウェルス ユニバーシティ | 多価キメラｏｓｐｃワクシノーゲンおよび診断用抗原 |
| WO2007093836A1 (en) | 2006-02-13 | 2007-08-23 | Cellectis | Meganuclease variants cleaving a dna target sequence from a xp gene and uses thereof |
| GB0603099D0 (en) * | 2006-02-16 | 2006-03-29 | Lontra Environmental Technolog | Rotary piston and cylinder devices |
| WO2008010009A1 (en) | 2006-07-18 | 2008-01-24 | Cellectis | Meganuclease variants cleaving a dna target sequence from a rag gene and uses thereof |
| WO2008059317A1 (en) | 2006-11-14 | 2008-05-22 | Cellectis | Meganuclease variants cleaving a dna target sequence from the hprt gene and uses thereof |
| JP5453097B2 (ja) | 2006-11-14 | 2014-03-26 | セレクティス | Ｈｐｒｔ遺伝子からのｄｎａ標的配列を切断するメガヌクレアーゼ変異型及びその使用 |
| WO2008093152A1 (en) | 2007-02-01 | 2008-08-07 | Cellectis | Obligate heterodimer meganucleases and uses thereof |
| CA2678526A1 (en) | 2007-02-19 | 2008-08-28 | Cellectis | Laglidadg homing endonuclease variants having novel substrate specificity and use thereof |
| WO2008102199A1 (en) * | 2007-02-20 | 2008-08-28 | Cellectis | Meganuclease variants cleaving a dna target sequence from the beta-2-microglobulin gene and uses thereof |
| WO2008149176A1 (en) * | 2007-06-06 | 2008-12-11 | Cellectis | Meganuclease variants cleaving a dna target sequence from the mouse rosa26 locus and uses thereof |
| EP2568048A1 (en) | 2007-06-29 | 2013-03-13 | Pioneer Hi-Bred International, Inc. | Methods for altering the genome of a monocot plant cell |
| EP3098309B1 (en) | 2007-10-31 | 2019-04-10 | Precision Biosciences, Inc. | Rationally-designed single-chain meganucleases with non-palindromic recognition sequences |
| WO2009074842A1 (en) | 2007-12-13 | 2009-06-18 | Cellectis | Improved chimeric meganuclease enzymes and uses thereof |
-
2008
- 2008-10-31 EP EP16163925.7A patent/EP3098309B1/en active Active
- 2008-10-31 ES ES16163925T patent/ES2732735T3/es active Active
- 2008-10-31 ES ES13165733.0T patent/ES2575412T3/es active Active
- 2008-10-31 EP EP19167904.2A patent/EP3578646A3/en active Pending
- 2008-10-31 DK DK16163925.7T patent/DK3098309T3/da active
- 2008-10-31 AU AU2008318430A patent/AU2008318430A1/en not_active Abandoned
- 2008-10-31 CA CA2704383A patent/CA2704383A1/en not_active Abandoned
- 2008-10-31 EP EP08845549.8A patent/EP2215223B1/en active Active
- 2008-10-31 JP JP2010532293A patent/JP5761996B2/ja active Active
- 2008-10-31 EP EP13165733.0A patent/EP2660317B1/en active Active
- 2008-10-31 DK DK08845549.8T patent/DK2215223T3/da active
- 2008-10-31 WO PCT/US2008/082072 patent/WO2009059195A2/en not_active Ceased
- 2008-10-31 DK DK13165733.0T patent/DK2660317T3/en active
- 2008-10-31 ES ES08845549T patent/ES2422291T3/es active Active
-
2010
- 2010-04-30 US US12/771,163 patent/US8445251B2/en active Active
-
2013
- 2013-05-20 US US13/897,923 patent/US20130267009A1/en not_active Abandoned
-
2015
- 2015-05-28 US US14/723,840 patent/US20150337335A1/en not_active Abandoned
- 2015-06-08 JP JP2015115646A patent/JP6050861B2/ja active Active
- 2015-09-18 US US14/858,989 patent/US9434931B2/en active Active
- 2015-09-18 US US14/858,986 patent/US9340777B2/en active Active
-
2016
- 2016-04-19 US US15/132,941 patent/US10041053B2/en active Active
- 2016-09-30 JP JP2016193485A patent/JP2017051190A/ja active Pending
-
2018
- 2018-07-02 US US16/025,747 patent/US20180340160A1/en not_active Abandoned
- 2018-11-22 JP JP2018219205A patent/JP2019062898A/ja active Pending
-
2020
- 2020-10-23 US US17/079,377 patent/US20210054354A1/en not_active Abandoned
- 2020-11-27 JP JP2020196770A patent/JP2021052770A/ja active Pending
-
2022
- 2022-11-25 JP JP2022187981A patent/JP2023029894A/ja active Pending
-
2023
- 2023-03-17 US US18/185,726 patent/US12351839B2/en active Active
-
2024
- 2024-10-24 JP JP2024187133A patent/JP2025028832A/ja active Pending
-
2025
- 2025-01-17 US US19/029,758 patent/US20250154485A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK3098309T3 (da) | Rationelt designet enkeltkædet meganuclease med ikke-palindrome genkendelsessekvenser | |
| BRPI0718796A2 (pt) | Nucleotídeo | |
| DE602007005217D1 (de) | Fahrradkette | |
| EP2132315A4 (en) | REOVIRUS HAVING MODIFIED SEQUENCES | |
| EP2209394A4 (en) | Armtasche | |
| DE502008000295D1 (de) | Nockenwelle | |
| DE602007004088D1 (de) | Kettenförderer | |
| DE502007002976D1 (de) | Nockenwelle | |
| ES2896053T8 (es) | Biogel | |
| FR2949750B1 (fr) | Chaine de propulsion | |
| EP2048992A4 (en) | UTENSIL | |
| EP2077854A4 (en) | OMEGA-conotoxins | |
| DE112008002937A5 (de) | Geräuscharmer Kettentrieb | |
| AT508202A3 (de) | Metallriemenkalander | |
| AT504336B8 (de) | Kettenrad | |
| FI20060661A0 (fi) | Kiinnike | |
| DK2088872T3 (da) | Overtrukne bærere | |
| SE0601926L (sv) | Kokkärl | |
| DE502006007220D1 (de) | Nockenwelle | |
| DE112007003228A5 (de) | Temperiervorrichtung | |
| UA15228S (uk) | Медальйон з ланцюжком | |
| ES1066538Y (es) | Llavero | |
| FI20065600A0 (fi) | Kampiakseli | |
| ES1068660Y (es) | Llavero | |
| GB0805010D0 (en) | Chain and sprocket guard |